secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001213900-23-049300
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma appoints Dr. T.S. Jiang as CSO after Dr. King resigns
--------------------------------------------------------------------

- Dr. Richard King resigned as Chief Scientific Officer effective June 13, 2023.
- Resignation not due to any disagreement with company operations, policies, or practices.
- Board appointed Dr. Tsung-Shann (T.S.) Jiang, current Chief Strategy Officer and director, as replacement CSO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023049300/0001213900-23-049300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023049300/ea180383-8k_abvcbiopharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-049300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer